A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells

• Main Authors: Patricia Martín-Rodríguez (Author), Borja Guerra (Author), Idaira Hueso-Falcón (Author), Haidee Aranda-Tavío (Author), Juan Díaz-Chico (Author), José Quintana (Author), Francisco Estévez (Author), Bonifacio Díaz-Chico (Author), Angel Amesty (Author), Ana Estévez-Braun (Author), Leandro Fernández-Pérez (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BCR-ABL1-STAT5 is an oncogenic signaling pathway in human chronic myelogenous leukemia (CML) and it represents a valid target for anti-CML drug design. Resistance to direct BCR-ABL1 inhibitors is a common clinical issue, so STAT5 inhibition has become an interesting alternative target. In this study...